3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
2
Immunoglobulin Light-chain Amyloidosis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Pain
1
Myoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Exanthema
1
Endometritis
1
Amyloidosis, Familial
1
Advanced Malignant Neoplasm
1
AA amyloidosis
1
Interventions
fludarabine phosphate
17
Mycophenolic Acid
17
Tacrolimus
15
Peripheral Blood Stem Cell Transplantation
14
Whole-Body Irradiation
13
Cyclophosphamide
12
Cyclosporine
11
Methotrexate
10
Antilymphocyte Serum
10
Busulfan
9
Radiotherapy
6
pembrolizumab
5
Methylprednisolone
5
Alemtuzumab
5
merphos
4
Transplantation
4
Rituximab
4
Melphalan
4
Flow Cytometry
4
Cord Blood Stem Cell Transplantation
4
Bexarotene
4
sargramostim
3
Therapeutics
3
Sirolimus
3
Panobinostat
3
Lenalidomide
3
Gemcitabine
3
Dexamethasone
3
Cyclosporins
3
zanolimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sezary Syndrome
×
Doxycycline
×
Clear all
NCT02341209
2021-04-27
CTCL
Rochester General Hospital
Phase 2
Terminated
1 enrolled